Meet with… Johnson & Johnson Innovation
How can Johnson & Johnson Innovation help you reach your goals?Johnson & Johnson Innovation (JJI) is supporting innovation in major life science clusters through the life science incubator, Johnson & Johnson Innovation, JLABS (JLABS), with the ultimate aim of enabling commercialization of new healthcare solutions for patients. We know what you, the innovator, need to get your science to patients. It is because of you that JJI created regional centers that host a team of science and transaction experts whose goal is to find high potential early-stage (pre-clinical proof-of-concept) innovation and form custom business solutions around it to help accelerate the science to the patient. The JJI team has broad deal-making capabilities with the flexibility to adapt the deal structures to the science.
On March 30, hear from Johnson & Johnson Innovation leaders as they provide an overview of J&J Innovation goals and mission, highlighting how J&J Innovation interacts with the entrepreneurial community through JLABS, JJDC, and other J&J Innovation initiatives.
Speakers will also be on hand to meet with a handful of applicants one-on-one after the presentation.
10:00am | Registration Opens and Networking
10:30am | JLABS Overview
11:00am | J&J Innovation Presentation and Q&A
12:00pm | Networking Lunch
12:30-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on March 3rd.
Johnson & Johnson Innovation Participating Representatives:
Ibraheem Badejo | Senior Director, New Ventures, J&J Innovation read bio»
Kuldeep Neote | Senior Director, New Ventures, J&J Innovation read bio»
Jennifer Hamilton | Senior Director, New Ventures, J&J Innovation read bio»
Thomas Luby | Senior Director, New Ventures, J&J Innovation read bio»
Rebecca Yu | Head of JLABS @ Toronto, J&J Innovation | JLABS read bio»
Presentation & Lunch
FREE | General Public
FREE | At the door
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on March 29th(or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on March 3rd. Your application will be reviewed and you will be notified of acceptance by March 17th. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.
About the Meet with… Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA’s Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
3 Place Ville Marie
Niveau L (Auditorium)
Montreal, QC H3B 0E7
Johnson & Johnson Innovation Participating Representatives Biographies:
Ibraheem Badejo, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation, Boston
Ibraheem (Ib) is Senior Director, New Ventures at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector. From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University. During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired. Ib received his BA degree in chemistry from Avila University. He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending.
Kuldeep Neote, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation, Boston
Kuldeep is Senior Director of New Ventures at the Johnson & Johnson Innovation, Boston. He focuses primarily on the areas of Oncology and Immunology. A trained molecular biologist with an extensive background in drug discovery, Kuldeep has been focused on the areas of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs. Formerly, Kuldeep was Research Advisor/Director in Global External R&D at Eli Lilly. Prior to Eli Lilly, he was a Discovery Scientist at Pfizer, where he initiated the chemokine receptor drug discovery platform that led to the discovery and further development of several clinical candidates. Earlier in his career, Kuldeep also cloned one of the first chemokine receptors while at Genentech. Kuldeep earned his BSc. in Microbial and Cellular Biology at the University of Calgary, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff’s disease.
Jennifer Hamilton, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation, Canada
Jennifer Hamilton is the innovation scout in Canada for the Johnson & Johnson Innovation. Based in Vancouver, British Columbia, she is responsible for identifying emerging healthcare technologies and business opportunities involving pharmaceutical, device, biomaterial, health IT and consumer innovations in Canada. Prior to joining J&J in 2010 she spent 17 years in venture capital as Venture Partner at UK-based Nomura Phase4 Ventures and as Investment Director with Rothschild Asset Management which managed two global publicly traded funds. Jennifer has a Ph.D. (Experimental Pathology/Lipid Metabolism) from the University of British Columbia.
Thomas Luby, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation
Tom is Senior Director of New Ventures at Johnson & Johnson Innovation, Boston. He focuses primarily on cardiovascular & metabolic; infectious diseases and Vaccines; and neurobiology. Prior to joining the Johnson & Johnson Family of Companies, Tom was the Sr. Director of Research Ventures at Shire Human Genetic Therapies. In this position, Tom played a central role in the evaluation, diligence, and deal processes across a number of successful early-stage investments in the rare disease space. He was member of the BOD at Armagen Technologies, led the collaboration with Nimbus Discovery, and was instrumental in establishing and leading the alliance that Shire put in place with Atlas Venture. Prior to this, Tom held a variety of research and development roles in both start-up and mid-sized biotech. He has worked on multiple discovery through Phase II programs in infectious disease, oncology, immunotherapy, and monogenetic disorders. His experience includes pre-clinical development, early-stage portfolio oversight, licensing, due diligence, company formation, alliance management, and key opinion leader outreach. Tom received his BS in Biology from State University of New York, his Ph.D. in Immunology from Tufts University, and was a post-doctoral fellow in yeast genetics at Harvard School of Public Health.
Rebecca Yu | Head of JLABS @ Toronto, Johnson & Johnson Innovation
Rebecca Yu is the Head of JLABS @ Toronto, Johnson & Johnson Innovation’s first JLABS incubator outside of the United States. JLABS @ Toronto is a partnership with Johnson & Johnson Innovation, Janssen Canada, the University of Toronto, MaRS Discovery District, MaRS Innovation and the Government of Ontario. Rebecca is responsible for overseeing and managing the business of JLABS @ Toronto including setting its strategic direction. As the local J&J Innovation ambassador to the life science innovation community in Ontario, Rebecca will be catalyzing and supporting the translation of science and technology into valuable solutions for patients and consumers across J&J’s sectors in pharma, medical devices and consumer healthcare. Before assuming her current responsibilities at JLABS @ Toronto, Rebecca was Director, Strategic Health Technology Assessment (HTA) in the Government Affairs & Market Access with Janssen Canada. Rebecca spent 15 years in Health Policy, Medical Affairs, and Government Affairs with Solvay Pharma, Procter & Gamble, Servier and Pfizer. Prior to joining industry, she practiced as a Clinical Pharmacist at The Wellesley Hospital. Rebecca is a graduate of the University of Toronto, Faculty of Pharmacy and is currently a pharmacist in Ontario. Rebecca was previously on the Board of Directors for the Markham Stouffville Hospital. She is currently a member of the Joint Steering Committee for the Neuroscience Catalyst Collaboration and on the Life Sciences Ontario’s Board of Directors.